Malignant Neoplasm of Breast Clinical Trial
Official title:
A Double-blind Randomized Trial of Interpectoral Nerve Block (Pecs 1 and 2) With Ropivacaine Versus Placebo Before Breast Cancer Surgery: Effects on Acute Postoperative Pain. (MIRs 04)
Compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery.
Before surgery, the 3rd interpectoral space will be identified. After aspiration, half of the solution of Ropivacaine 5 mg/ml not exceeding 3 mg/kg of maximal dose and 30 ml of maximal volume or saline (not exceeding 30 ml of maximal volume) will be injected into the interpectoral space underneath the pectoralis major muscle for the Pecs 1 block. The other half of the solution will be injected above the serratus anterior muscle at the third rib. Evaluation of the percentage of patients treated with step 2 or 3 analgesics during the three postoperative hours. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
| Completed |
NCT01953003 -
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT01395706 -
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
|
Phase 2 | |
| Enrolling by invitation |
NCT05486520 -
Low-field MRI for Breast Cancer Screening
|
N/A | |
| Completed |
NCT05159778 -
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
|
Phase 2 | |
| Active, not recruiting |
NCT03379428 -
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
| Withdrawn |
NCT03261323 -
Breast Reconstruction Following Breast Cancer in Very High Risk Patients
|
N/A | |
| Recruiting |
NCT04669873 -
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
|
N/A | |
| Completed |
NCT02408393 -
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
|
Phase 3 | |
| Completed |
NCT03289819 -
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
|
Phase 2 | |
| Completed |
NCT02495363 -
Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
|
||
| Completed |
NCT03159195 -
Ibrance Real World Insights
|
||
| Completed |
NCT03425656 -
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT05033756 -
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
|
Phase 2 | |
| Not yet recruiting |
NCT01641003 -
Isolation and Characterization of Cancer Stem Cells Using iFP Technique
|
N/A | |
| Active, not recruiting |
NCT05364450 -
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
| Active, not recruiting |
NCT02204098 -
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT06251544 -
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
|
Phase 1 |